Xechem, Inc., and Xechem International, Inc. v. Bristol-Myers Squibb Company

U.S. Court of Appeals, Seventh Circuit · Decided 2004-06-23

Cited by 225 later decision(s) in our corpus · see the citation network in Lexace

Open in Lexace · Ask the AI about this case

From the opinion

EASTERBROOK, Circuit Judge. The Hatch-Waxman amendments to the Food and Drug Act entitle pharmaceutical companies that first bring a drug to market to a five-year period of exclusivity, even if the drug is unpatented. 21 U.S.C. § 355 . Bristol-Myers Squibb was first to market with paclitaxel, a compound derived from the bark of the yew tree an…

Read the full opinion (source) ↗


Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Citation figures are counts of later citing opinions in our corpus and may be incomplete; always read and Shepardize the full opinion before relying on it.